General
Preferred name
Carboxyamidotriazole
Synonyms
L-651582 ()
L 651582 ()
L-651582 Orotate ()
CAI Orotate ()
Carboxyamidotriazole Orotate ()
L-651,582 ()
L651582 ()
Carboxyamidotriazole (Orotate) ()
L-651582 (Orotate) ()
CAI (Orotate) ()
CAI ()
L-651582 Orotate, CAI Orotate ()
NSC-609974 ()
P&D ID
PD040048
CAS
187739-60-2
99519-84-3
Tags
available
drug candidate
Drug indication
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Potent and selective alpha7 nAChR agonist (Tocris Bioactive Compound Library)
DESCRIPTION L-651,582 is a novel inhibitor of both cAMP-phosphodiesterases and GMP-phosphodiesterases. It is also an orally active calcium channel blocker. It prevents oxidative phosphorylation in cancer cells and exhibits inhibition of pro-inflammatory cytokines in tumor associated macrophages. It may be used as a potential anti-cancer drug. It ameliorates experimental colitis by inhibiting nuclear factor-κB activation, colonic fibrosis and cytokine production. It has antimetastatic, antiangiogenic and antiproliferative activity in vivo. It displays selectivity towards numerous mismatch repair-deficient tumor cell lines in vitro. It blocks intracellular and mitochondrial calcium entry and flux, resulting in inhibition of calcium-release-activated calcium channel (CRAC) function, cell proliferation and maintenance of mitochondrial membrane potential. (BOC Sciences Bioactive Compounds)
DESCRIPTION Carboxyamidotriazole orotate (CTO) is the orotate salt form of carboxyamidotriazole (CAI), an orally bioavailable small molecule with potential antiangiogenic and antiproliferative activities. Carboxyamidotriazole binds to and inhibits non-voltage-operated calcium channels, blocking both Ca2+ influx into cells and Ca2+ release from intracellular stores, resulting in the disruption of calcium channel-mediated signal transduction. CAI inhibits PI3 activity and vascular endothelial growth factor (VEGF) signaling. This may inhibit endothelial proliferation, tumor cell growth, invasion and metastasis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) . (BOC Sciences Bioactive Compounds)
Cell lines
0
Organisms
1
Compound Sets
13
Axon Medchem Screening Library
3185
BOC Sciences Bioactive Compounds
l-651-582-cas-99519-84-3-item-402133
carboxyamidotriazole-orotate-cas-187739-60-2-item-84-462471
Cayman Chemical Bioactives
28732
ChEMBL Drugs
CHEMBL95431
Drug Repurposing Hub
DrugBank
DB11960
DrugMAP
DMWTPCA
DrugMatrix
MedChem Express Bioactive Compound Library
HY-16126
HY-16125
ReFrame library
Selleckchem Bioactive Compound Library
carboxyamidotriazole-orotate
TargetMol Bioactive Compound Library
T14871
Tocris Bioactive Compound Library
3086
External IDs
31
Properties
(calculated by RDKit )
Molecular Weight
423.01
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
3.2
TPSA
116.89
Fraction CSP3
0.06
Chiral centers
0.0
Largest ring
6.0
QED
0.61
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Membrane Transporter/Ion Channel
Metabolism
Neuronal Signaling
Target
Calcium Channel
CXCL8
Ca channel blocker
Primary Target
Non-selective Cav Channels
MOA
Blocker
calcium channel blocker
Solubility
Soluble in DMSO
Source data